HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Novartis Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Novartis Intelligence Report

Generated from 36 signals · 9 evidence sources

Type

Company Intelligence Report

Generated

Jul 22, 2026

Confidence

Moderate Confidence · 72%

Evidence

184 items

Sources

55

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Novartis maintains an active intelligence profile across Oncology, mTOR Inhibitor, Immunology, Transplantation, AKT Inhibitor. 36 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 72% across 9 tracked sources. Highest-priority development: FDA Accepts Supplemental Application for Emgality (Galcanezumab). Portfolio development. FDA Accepts Supplemental Application for Emgality (Galcanezumab) is an owned Novartis portfolio development in Neurology · CGRP Inhibitor.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 17, 2026

    Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

    Ophthalmology · Ocular Inflammation · opportunity score 175

    View detail
  2. portfolio

    FDA Accepts Supplemental Application for Emgality (Galcanezumab)

    FDA approval

    View detail
  3. portfolio

    AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

    FDA approval

    View detail
  4. competitive

    Novartis (named in signal competitive context)

    Elevated competitive pressure

    View detail
  5. competitive

    FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Potential competitive pressure

    View detail
  6. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Other | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — TEGRETOL (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — GLEEVEC (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — TEGRETOL (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 6110 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review. Competitiva linkage surfaces 2 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Novartis (named in signal competitive context)

    Moderate Confidence · 72%

    Elevated competitive pressure

    Source: FDA, Competitiva

    View evidence

  • FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Moderate Confidence · 65%

    Potential competitive pressure

    Source: Humanexa Signals, Competitiva

    View evidence

  • FDA Accepts Supplemental Application for Emgality (Galcanezumab)

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

    Low Confidence · 0%

    FDA approval

    Source: Novartis, FDA, Portfolio

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Other | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TEGRETOL (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — GLEEVEC (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TEGRETOL (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — GLEEVEC (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MAYZENT (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — KISQALI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LITHIUM CARBONATE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PADCEV (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Priority Review for KISQALI Supplement by Novartis

    Oncology · CDK4/6 Inhibitor

  • FDA Approves Supplemental Application for IBRANCE (Palbociclib)

    Oncology · CDK4/6 Inhibitor

  • Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment

    Nephrology · Complement Inhibition

  • FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

    Oncology · Combination Therapy

  • Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

    Ophthalmology · Ocular Inflammation

  • FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

    Oncology · mTOR Inhibitor

  • FDA Accepts Supplement for Mekinist (Trametinib) by Novartis

    Oncology · MEK Inhibitor

  • AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

    Oncology · AKT Inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.